Table 3. The association of RGS1expression and other parameters.
| Clinicopathological features | RGS1 | Total No. (%) |
P value |
||
|---|---|---|---|---|---|
| ≤ 35 (N = 16) | >35 (N = 28) | ||||
| No. (%) | No. (%) | ||||
| LDH (IU/L) | ≤ 250 | 13 (81.3) | 2 (7.1) | 15 (34.1) | <0.001 * |
| >250 | 3 (18.8) | 26 (92.9) | 29 (65.9) | ||
| Clinicopathological features | mTOR score level |
Total
No. (%) |
P
value |
||
| > 1 (n = 27) | ≤ 1 (n = 17) | ||||
| No. (%) | No. (%) | ||||
| LDH (IU/L) | ≤ 250 | 2 (7.4) | 13 (76.5) | 15 (34.1) | <0.001 ** |
| >250 | 25 (92.6) | 4 (23.5) | 29 (65.9) | ||
| FLC | Kappa-LC | 2 (5.4) | 1 (14.3) | 3 (6.8) | 0.074 ** |
| Lambda-LC | 4 (10.8) | 1 (14.3) | 5 (11.4) | ||
| No FLC | 31 (83.8) | 5 (71.4) | 36 (81.8) | ||
** P-value < 0.05: Significant; P-value < 0.01: Highly significant (Chi-square test).
* OR = 56.3 (95CI: 8.35–380.1); Sig. Pos. Risk.